Abstract
Emerging data suggest that COX-2 is involved at various steps of the process of malignant transformation and tumor progression. The current article reviews the latest data linking COX-2 with the various gynecological cancers. COX-2 overexpression has been reported in most gynecological neoplasms, including breast, cervix, endometrial and epithelial ovarian cancers. COX-2 expression promotes tumor cell proliferation, reduces apoptosis and induces angiogenesis. As a result, tumors expressing COX-2 are reported to exhibit a more aggressive phenotype and clinical behavior. Women whose tumors over-express COX-2 tend to have a lower response to standard therapy and shorter survival times. In-vitro studies have shown that COX-2 inhibitors can inhibit tumor cell growth and reduce angiogenesis. On the basis of the current data and the clinical availability of safe inhibitors, COX-2 is a perfect target for cancer prevention and therapy. A number of trials are investigating the benefits of combining COX-2 inhibitors with existing treatment modalities in the management of breast, ovarian and cervical cancers. In addition, large prevention trials are in the planning stage.

This publication has 29 references indexed in Scilit: